Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Average Target Price of $8.20Defense World · 3 days ago
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?GuruFocus · Oct 12, 2026
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?PRNewsWire · Oct 12, 2026
Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of InvestorsNewsfile Corp · Oct 8, 2026
Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal RightsNewsfile Corp · Oct 6, 2026
Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law ViolationsNewsfile Corp · Oct 2, 2026Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.24 | -$0.34 | Miss |
| Apr 27, 2026 | -$0.31 | -$0.25 | Beat |
| Feb 24, 2026 | -$0.31 | -$0.31 | Beat |
| Oct 29, 2025 | -$0.29 | -$0.31 | Miss |
| Jul 29, 2025 | -$0.29 | -$0.28 | Beat |
| May 1, 2025 | -$0.29 | -$0.28 | Beat |